The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice

Paula I. Gonzalez-Ericsson, Elisabeth S. Stovgaard, Luz F. Sua, Emily Reisenbichler, Zuzana Kos, Jodi M. Carter, Stefan Michiels, John Le Quesne, Torsten O. Nielsen, Anne Vibeke Lænkholm, Stephen B. Fox, Julien Adam, John M.S. Bartlett, David L. Rimm, Cecily Quinn, Dieter Peeters, Maria V. Dieci, Anne Vincent-Salomon, Ian Cree, Akira I. HidaJustin M. Balko, Harry R. Haynes, Isabel Frahm, Gabriela Acosta-Haab, Marcelo Balancin, Enrique Bellolio, Wentao Yang, Pawan Kirtani, Tomoharu Sugie, Anna Ehinger, Carlos A. Castaneda, Marleen Kok, Heather McArthur, Kalliopi Siziopikou, Sunil Badve, Susan Fineberg, Allen Gown, Giuseppe Viale, Stuart J. Schnitt, Giancarlo Pruneri, Frederique Penault-Llorca, Stephen Hewitt, E. Aubrey Thompson, Kimberly H. Allison, William F. Symmans, Andrew M. Bellizzi, Edi Brogi, David A. Moore, Denis Larsimont, Deborah A. Dillon, Alexander Lazar, Huangchun Lien, Matthew P. Goetz, Glenn Broeckx, Khalid El Bairi, Nadia Harbeck, Ashley Cimino-Mathews, Christos Sotiriou, Sylvia Adams, Shi wei Liu, Sibylle Loibl, I. Chun Chen, Sunil R. Lakhani, Jonathan W. Juco, Carsten Denkert, Elizabeth F. Blackley, Sandra Demaria, Roberto Leon-Ferre, Oleg Gluz, Dimitrios Zardavas, Kenneth Emancipator, Scott Ely, Sherene Loi, Roberto Salgado, Melinda Sanders

Research output: Contribution to journalReview articlepeer-review

79 Scopus citations

Fingerprint

Dive into the research topics of 'The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice'. Together they form a unique fingerprint.

Medicine & Life Sciences